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Introduction
Patients after surgery or with end-stage joint disease often experience moderate to severe pain. One-to-three out of every four patients with moderate to severe acute pain following surgery report poor pain control [1] . Inadequate management of moderate to severe pain has been reported to be associated with an increased risk of potentially life-threatening complications such as deep vein thrombosis or myocardial infarction [2, 3] . Therefore, effective control of moderate to severe pain is a pressing unsolved issue in post-surgery patient care.
Presently, opioids, such as oxycodone, morphine, and pethidine are considered to be the standard care to relieve moderate to severe pain [4] . However, their utility is often limited by an array of gastrointestinal and central nervous system adverse effects including nausea, vomiting, constipation, dizziness, somnolence, and headache [5] [6] [7] [8] . A comparably effective analgesic drug with lower adverse event (AE) incidence is urgently needed for the treatment of moderate to severe pain.
Tapentadol is an analgesic with a dual mechanism that combines m-opioid receptor agonism with norepinephrine reuptake inhibition [9] . An immediate release (IR) formulation of three doses of tapentadol (50, 75, and 100 mg) was approved by the US Food and Drug Administration (FDA) in November 2008 for the relief of moderate to severe acute pain in patients aged 18 years old and older. Preclinical studies showed that opioid drugs (morphine) exhibited 50-fold greater affinity for the rat m-opioid receptor compared with tapentadol, while providing pain freedom only 2-3 fold than tapentadol [10] . At the present, there are articles in which the new oral agent, tapentadol IR, is effective in providing pain relief from moderate to severe pain with similar efficacy to oxycodone HCI IR 10 mg and significantly better gastrointestinal tolerance [11, 12] . However, some other articles show contrasting results with respect to efficacy and AEs. Meanwhile, there is no meta-analysis that has been performed on this subject.
Thus, this meta-analysis was conducted to get a comprehensive review and verify whether the efficacy of tapentadol IR (50, 75, or 100 mg) was similar to oxycodone HCL IR 10 mg and whether the AEs were lower than oxycodone HCL IR in patients with moderate to severe pain.
Methods

Data Sources and Search Strategy
We searched Medline, Pubmed, and the Cochrane Collaboration Library from inception to July 2015, without restriction of language. FDA data and Clinical Trials (http://www.clinicaltrials.gov) were also searched. In our search strategy, the following terms were used: "tapentadol," "nucynta," "IR," "immediate release," and "pain." These terms were adjusted to comply with the relevant rules in each database.
Study Selection
Titles and abstracts of all retrieved citations were screened by two independent reviewers (J.P.X. and G.J.W.) to identify potential studies, and then full texts of those potential studies were retrieved. Every discrepancy was resolved by discussion and a third reviewer was involved if there still was a conflict.
Inclusion Criteria
Randomized controlled trials (RCTs) of tapentadol IR for the treatment of moderate to severe pain defined by the World Health Organization (WHO) diagnostic criteria were included [13] . Inclusion criteria for the metaanalysis were: 1) patients: inclusive of any ethnic origin and aged over 18; 2) interventions: fixed doses of tapentadol IR; 3) comparison intervention: oxycodone HCL IR 10 mg or placebo; 4) report of at least one of the following outcomes: (a) SPID 48 (the sum of pain intensity difference over 48 hours), (b) TOTPAR 48 (total pain relief over 48 hours), (c) patient global impression of change (PGIC) [14] , and (d) AEs. Trials of patients without moderate to severe pain, non-randomized trials, case reports, editorials, letters to the editors, trials without comparison group, and trials without tapentadol IR oral formulation were all excluded.
Data Extraction
Two reviewers independently screened articles by the inclusion criteria, and any discrepancies were resolved by consensus. In those articles, tapentadol IR doses of 50, 75, or 100 mg were given every 4-6 hours, and all treatments were administered by same vehicles with the same delivery devices. From each study, we extracted study characteristics, baseline characteristics, and prespecified outcomes of efficacy and safety.
Risk of Bias
Two reviewers independently applied the Cochrane Risk of Bias tool to assess the risk of bias of randomized trials [15] , including random sequence generation, allocation concealment, blinding, incomplete data regarding outcome, selective reporting, and other items (i.e., funder, and incomplete information in the text).
Data Synthesis and Analysis
All outcomes were pooled by using RevMan 5.2 software [16] . For continuous and dichotomous data, differences were calculated by weighted mean difference Figure 1 Flow chart of study selection process.
Tapentadol IR for Moderate to Severe Pain (WMD) and risk ratio (RR), respectively. All results were estimated by 95% CI. Heterogeneity was assessed by chi-square test and I 2 statistics, if I 2 < 50%, the fixedeffect model with Mantel-Haenszel method was used; otherwise, the random-effect model was adopted.
Results
Sixty-three articles that met our inclusion criteria were identified after being reviewed by two independent reviewers; a total of nine RCTs (n ¼ 3961) [11, 12, [17] [18] [19] [20] [21] [22] [23] met the final inclusion criteria for the meta-analysis ( Figure 1 ).
Study Characteristics
The characteristics and results of the included studies are shown in Table 1 . All included trials were randomized, double-blind, placebo-controlled studies. Trial durations ranged from 3 to 10 days. Mean age of patients was 48.3 6 13.1 years, and 22.2% were men. The proportion of the participants with baseline pain intensity of severe pain was 68.6%. Participants in most trials were mainly middle-aged and overweight adults. Mean body mass index of patients was 28.2 6 5.7; all studies included a placebo group. Tapentadol IR was administered orally, in a dose of 50, 75, or 100 mg once every 4-6 hours in all trials. Cause of moderate to severe pain included bunionectomy [11, 12, 17, 19, 20, 23] , hysterectomy [21] , end-stage joint disease [18] , and joint replacement surgery [22] .
Risk of Bias
A low risk for bias for the various items was assessed in all studies. All studies were randomized controlled, double blind, and all were funded by industry (Table 2) . Figure 2 Comparison of sum of pain intensity difference over 48 hours of all three doses of tapentadol IR or placebo.
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However, random sequence generation was unclear in six RCTs [12, 17, [20] [21] [22] [23] .
Efficacy
Sum of Pain Intensity Difference over 48 Hours
Sum of pain intensity difference (SPID) was calculated as the sum of the differences between the pain scores over a period of time. Differences between pain intensity values at the start and end of a measurement period were dealt with by the trapezoidal rule. Because SPID scores represent differences from pre to post, positive SPID values indicate improvements. As shown in Figure 2 , all three doses of tapentadol IR produced statistically significant (P < 0.01 or 0.0001) improvements compared to placebo. As shown in Figure 3 , there were no significant differences between any dose of tapentadol IR and oxycodone HCL IR 10 mg, although the difference approached significance (P ¼ 0.06) in favor of tapentadol IR for the 50 mg dose. Table 3 summarizes these results and includes comparisons among the doses of tapentadol, showing that 75 mg was superior to 50 mg, whereas 75 and 100 mg did not differ.
Total Pain Relief over 48 Hours
Total pain relief (TOTPAR) was calculated as the sum of pain relief scores over a period of time. Differences between pain relief values at the start and end of a measurement period were dealt with by the composite trapezoidal rule. Data from six trials showed that, compared with placebo, significant improvements in TOTPAR 48 were observed with all three doses of tapentadol IR (P ¼ 0.04 or P < 0.00001) ( Table 3 ). As shown in Figure 4 , Tapentadol IR 50 and 75 mg vs. oxycodone HCL IR 10 mg was associated with similar improvement in TOTPAR 48 , the pooled WMD were -2.83 (P ¼ 0.54) and -0.92 (P ¼ 0.83) respectively; only one article [12] showed that tapentadol IR 100 mg provided higher scores than oxycodone HCL IR 10 mg in TOTPAR 48 (P ¼ 0.007). Compared with tapentadol IR 50 mg, tapentadol IR 75 mg demonstrated significantly higher TOTPAR 48 (P ¼ 0.0009). There was one article [17] that showed tapentadol IR 75 mg could provide comparable effects in TOTPAR 48 than tapentadol IR 100 mg (P ¼ 0.08) ( Table 3) .
Patient Global Impression of Change (PGIC)
PGIC was assessed once at the end of treatment or at study withdrawal; patients indicated their response to the statement "Since I began study medication, my overall status is . . ." using a scale from 1 (very much improved) to 7 (very much worse). We compared the percentage of patients who rated their status as'much improved' or 'very much improved' on the PGIC [18] . The pooled data demonstrated that, compared with placebo, significant improvements in TOTPAR 48 were observed in all three doses of tapentadol IR (all P < 0.00001) ( Table 3 ). As shown in Figure 5 , tapentadol IR 50 and 75 mg showed similar effects in PGIC compared with oxycodone HCL IR 10 mg (P ¼ 0.72 or 0.45).
There was also no statistical difference between tapentadol IR 50 and 75 mg (P ¼ 0.23) ( Table 3) .
Safety
Nausea
As shown in Figure 6 , the risk incidence of nausea of patients treated with tapentadol IR 50 or 75 mg was Figure 3 Comparison of sum of pain intensity difference over 48 hours of all three doses of tapentadol IR or oxycodone HCL IR 10 mg.
significantly lower than oxycodone HCL IR 10 mg (P ¼ 0.002 or P ¼ 0.02). However, compared with oxycodone HCL IR 10 mg, tapentadol IR 100 mg showed no significant lower incidence in nausea (P ¼ 0.46).
Vomiting
As shown in Figure 7 , tapentadol IR 50 showed significantly less vomiting compared to oxycodone HCL IR 10 mg (P < 0.00001). However, there was no statistical difference in incidence of vomiting between tapentadol IR 75 and oxycodone HCL IR 10 mg (P ¼ 0.25). Meanwhile, a comparable vomiting incidence was shown in tapentadol IR 100 vs. oxycodone HCL IR 10 mg (P ¼ 0.35).
Constipation
As shown in Figure 8 , when we compared tapentadol IR 50 and 75 mg with oxycodone HCL IR 10 mg, the constipation incidence was significantly lower in tapentadol IR 50 and 75 mg (P ¼ 0.03 or P < 0.0001).
Meanwhile, compared with oxycodone HCL IR 10 mg, treatment with tapentadol IR 100 mg showed a numerically lower incidence in constipation (P ¼ 0.09).
Other Adverse Events
In AEs of the nervous system (i.e., dizziness, somnolence, and headache), the pooled data showed that the incidence of most multiple doses of tapentadol IR were similar as oxycodone HCL IR 10 mg (all P > 0.05), but tapentadol IR 50 mg showed a significantly lower incidence than oxycodone HCL IR 10 mg in dizziness (P ¼ 0.0001), while tapentadol IR 100 mg showed a Tapentadol IR for Moderate to Severe Pain significantly higher incidence of somnolence than oxycodone HCL IR 10 mg (P ¼ 0.02) ( Table 3 ).
For the incidence of total AEs, tapentadol IR 50 and 100 mg showed no statistical difference when compared with oxycodone HCL IR 10 mg (P ¼ 0.07 or 0.41). The tapentadol IR 75 mg showed a significantly lower incidence of total AEs than oxycodone HCL IR 10 mg (P ¼ 0.0003) ( Table 3) .
Compared with oxycodone HCL IR 10 mg, tapentadol IR 50 mg showed a significantly lower incidence of discontinuation due to AEs (P ¼ 0.001). Meanwhile, tapentadol IR 75 and 100 mg showed a numerically lower incidence of discontinuation than oxycodone HCL IR 10 mg (P ¼ 0.10 or 0.11) ( Table 3) .
Discussion
Tapentadol is an analgesic with dual mechanisms that combines m-opioid receptor agonism with norepinephrine reuptake inhibition. Thus, tapentadol provides good analgesia and lower gastrointestinal AEs than morphine [24] [25] [26] . In this systematic review, we mainly assessed the efficacy and safety of tapentadol IR 50, 75, and 100 mg for patients with moderate to severe pain and tried to find out the optimal dosage of tapentadol IR to control moderate to severe pain. For AEs, this systematic review evaluated gastrointestinal (i.e., nausea, vomiting, constipation) and nervous system (i.e., dizziness, somnolence, and headache) tolerability. Tapentadol IR 50 and 75 mg were associated with better gastrointestinal tolerance compared with oxycodone HCL IR 10 mg. However, the tapentadol IR 100 mg showed similar incidence of gastrointestinal AEs as oxycodone HCL IR 10 mg. Still, all three doses of tapentadol IR Figure 8 Comparison of the incidence of constipation of all three doses of tapentadol IR or oxycodone HCL IR 10 mg.
showed numerically lower incidence of gastrointestinal AEs than oxycodone HCL IR 10 mg. Comparison of nervous system AEs showed tapentadol IR 50 mg had a significantly lower incidence of dizziness than oxycodone HCL IR 10 mg, and tapentadol IR 100 mg showed a significantly higher incidence of somnolence than oxycodone HCL IR 10 mg. Meanwhile, in terms of other nervous system AEs, all three tapentadol IR doses showed similar incidence compared with oxycodone HCL IR 10 mg.
Tapentadol IR 50 and 75 mg also showed a lower incidence of total AEs than oxycodone HCL IR 10 mg, while tapentadol IR 100 mg showed a similar incidence as oxycodone HCL IR 10 mg. In addition, tapentadol IR 50 mg showed a lower incidence of discontinuation than oxycodone HCL IR 10 mg. However, there was no significant statistical difference in the incidence of discontinuation when tapentadol IR 75 and 100 mg was compared with oxycodone HCL IR 10 mg.
There are several potential limitations in this study.
Because the proportions of participants with moderate to severe pain in the nine studies were varied, the heterogeneity might bias conclusions of some findings of this meta-analysis. Thus, to examine the contribution of participants' baseline characteristics with sensitivity analyses or meta-regression is necessary. Further, the quantity of included studies was small so more studies of high quality were needed for analyses on active comparators. Additionally, the result of this study is only applicable to moderate to severe pain of post-surgery or end-stage joint disease; tumor-related pain was often treated by tapentadol extended release [27] . However, this study met most of the methodological criteria of systematic reviews [28] , and all included studies were randomized double-blind, placebo-controlled trials.
According to the quality-assessment scale, the quality of each study in this meta-analysis was conforming.
Conclusion
In summary, treatment with all three doses of tapentadol IR can provide significant relief for moderate to severe pain, with similar efficacy to oxycodone HCL IR 10 mg. Tapentadol 75mg showed more analgesic efficacy than 50mg. Tapentadol IR 50 and 75 mg had better gastrointestinal tolerability than oxycodone HCL IR 10 mg but tapentadol 100 mg showed a similar incidence of gastrointestinal AEs and higher nervous system AEs than oxycodone HCL IR 10 mg. Furthermore, tapentadol IR 75 mg might be the best dosage to control moderate to severe pain.
